Evotec Biologics Partners with BARDA to Enhance Antibody Production Against Ebola

Evotec SE has announced that its subsidiary, Just – Evotec Biologics, has entered an agreement with the Biomedical Advanced Research and Development Authority (BARDA) to enhance the biomanufacturing of antibodies targeting Ebola and related viruses. This project aims at optimizing the production of monoclonal antibody cocktails, which are critical in combating filovirus diseases.

The agreement supports U.S. preparedness for viral outbreaks, emphasizing the need for scalable and cost-effective therapeutic solutions. Just – Evotec Biologics will utilize its advanced technology platforms to optimize the manufacturing process, enhancing the scalability and efficiency of antibody production.

The project, valued at up to $10 million, underscores the importance of speed and resilience in handling public health emergencies. The initiative will leverage federally funded technologies to develop robust manufacturing processes capable of responding swiftly to future health security threats.